GlassScriptPhysician profile
Brett Neill
NPI 1679006522
$1,799.03
in general payments reported to CMS, 2019-2025
22 companies · $305 in 2025
The $305 reported for 2025 was less than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $97.10 · 2021: $93.98 · 2022: $449 · 2023: $107 · 2024: $747 · 2025: $305.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,069 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,069.09 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $303.75 | 2024-2025 | Sotyktu |
| Bioventus LLC | $196.94 | 2022 | |
| Lilly USA, LLC | $176.72 | 2021-2025 | Ebglyss, Taltz |
| Amgen INC. | $151.49 | 2020-2025 | Otezla, Otezla |
| Janssen Biotech, INC. | $144.49 | 2022-2025 | Tremfya |
| Abbvie INC. | $141.80 | 2021-2025 | |
| Convatec INC. | $140.15 | 2024 | |
| Organogenesis INC. | $89.32 | 2023-2024 | Puraply |
| Genzyme Corporation | $63.79 | 2025 | |
| Sun Pharmaceutical Industries INC. | $52.46 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $51.89 | 2024-2025 | Libtayo, Dupixent |
| Ucb, INC. | $44.57 | 2024-2025 | Bimzelx |
| Biofrontera INC. | $34.15 | 2023-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Pfizer INC. | $32.59 | 2020 | |
| Galderma Laboratories, L.P. | $30.62 | 2025 | Nemluvio |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $26.68 | 2025 | |
| Almirall LLC | $25.82 | 2024 | Seysara |
| Biotissue Holdings INC. | $22.70 | 2022 | |
| Mayne Pharma Commercial LLC | $19.81 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.28 | 2023 | |
| Merck Sharp & Dohme LLC | $17.24 | 2021 | |
| Genentech USA, INC. | $12.77 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brett Neill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.